Quality by design based development, characterization, and optimization of a biohybrid collagen-silver nanoparticles with mupirocin.

Wound healing is a complex process triggered by skin injury, and has increased attention on chronic wounds due to serious health problems and decline in life quality. The development of a biohybrid formulation using a synergistic technique involves a promising strategy for addressing various pathological manifestations of chronic wounds. This research aims to investigate the efficacy of beta-cyclodextrin (BCD) and sodium borohydride as a reducing agent in development of biohybrid collagen-based silver nanoparticles through a chemical reduction method with mupirocin (Col-AgNP-MUP). The Col-AgNP-MUP was developed and optimized to determine the best-reducing agent employing response surface methodology with critical quality attributes. The optimized formulation was characterized and demonstrated for its in-vitro cytotoxicity using a 3T3-L1 fibroblast cell line. The formulation, developed through chemical reduction method with BCD. The UV-vis spectroscopy exhibits a λmax at 402 nm and compatibility through Fourier transform Infrared spectroscopy (FTIR) studied. The particle size, polydispersity index (PDI), zeta potential(ZP) and entrapment efficiency(EE) were determined to be 188.4 nm, 0.176, 36.7 mV and 85.21 % respectively. The X-ray diffraction (XRD) indicates an amorphous peak owing to collagen matrix. Atomic force microscopy (AFM) and High-Resolution Transmission electron microscopy (HR-TEM) confirm a spherical shape of particles. In-vitro drug release studies showed efficacy at pH 7.4, suitable for the increased pH of chronic wounds. The in-vitro biocompatibility investigations demonstrated the Col-AgNP-MUP did not cause any toxicity. The study paves the work for developing a novel anti bacterial wound dressing. [ABSTRACT FROM AUTHOR]